 |
UCLA » UCLA Healthcare » UCLA Neurology » Stroke Center » Victor Marder, MD |  |
|
Victor Marder, MD
Homepage Victor Marder graduated from Johns Hopkins University School of Medicine in 1959 and received his house-staff training at Johns Hopkins Hospital and Strong Memorial Hospital in Rochester, New York. He received research and clinical training in hematology and vascular medicine at the National Institutes of Health (1961-1964, 1966-1968) in the laboratory of N. Raphael Shulman and spent one year in the laboratory of Maxime Seligmann and Marie-Jo Larrieu at the Hopital St. Louis in Paris, France from 1964-1965. Dr. Marder's first faculty appointment was at Temple University Health Sciences Center from 1968 to 1977, where he advanced in the Department of Medicine from Assistant Professor of Medicine to full Professor of Medicine. Dr. Marder was a member of the Specialized Centers of Research (SCOR) in Thrombosis, directing the Fibrinolysis Section, and served as Chief of the Section on Thromboembolic Diseases in the Department of Medicine, under Professor and Chair, Sol Sherry. In 1977, Dr. Marder moved to the University of Rochester School of Medicine and Dentistry, assuming the position of Chief of Hematology, Department of Medicine. He developed and directed a Program Project in coagulation, hemostasis and thrombosis for 15 years and published in the fields of fibrinogen and von Willebrand factor biochemistry, endothelial cell physiology, and translational in clinical studies of thrombolytic therapy and prophylactic anticoagulation. In 1999, Dr. Marder joined the faculty at the David Geffen School of Medicine at UCLA as Director of the Vascular Medicine Program at Los Angeles Orthopaedic Hospital and the Division of Hematology/Medical Oncology in the Department of Medicine. Dr. Marder is Co-Director of the Hematology/Medical Oncology Training Program and directs the NIH-funded "Training for Academic Hematology" (2002-2007). Dr. Marder is a recipient of a Distinguished Career Award from the International Society on Thrombosis and Haemostasis (1995) and has served as Chair of the ISTH Council (1986-1988) and as President of the XVIIth ISTH Congress in Washington, DC (1999). His current research interest is in thrombolytic treatment using direct fibrinolytic agents, notably plasmin, and with a focus on such application in the management of acute ischemic stroke. |
|
